BSX vs UNH

Boston Scientific (BSX) is a well-established large-cap medical device company. While it demonstrates solid financial health and consistent, healthy operational growth (Q1 2026 revenue +11.6% reported, +9.4% organic) and strategic acquisitions (like the proposed Penumbra deal), its fundamental profile is misaligned with 10x growth potential within 3-5 years. A market capitalization of $80.16 billi...

UnitedHealth Group (UNH) remains a robust, high-quality mega-cap in the mature and highly regulated healthcare sector. Q1 2026 adjusted EPS of $7.23, a recent dividend increase to $2.32, and some analyst upgrades (e.g., Truist to $440, Goldman Sachs Conviction Buy) reflect solid operational performance and financial strength. However, these are characteristics of a stable compounder, not a company...